Weizu P. Li

No. 81 Meishan Road
Hefei, 230032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

TRPC6-mediated calcium signaling is involved in T2DM-induced hepatic steatosis and fibrosis and the modulation of ginsenoside Rg1.

TRPC6-mediated calcium signaling is involved in T2DM-induced hepatic steatosis and fibrosis and the modulation of ginsenoside Rg1.

Journal: Journal of pharmacological sciences

Published: March 13, 2026

TRPC6-TXNIP-NLRP3 signaling axis is involved in type 2 diabetes-associated cognitive dysfunction and the intervention of ginsenoside Rg1.

TRPC6-TXNIP-NLRP3 signaling axis is involved in type 2 diabetes-associated cognitive dysfunction and the intervention of ginsenoside Rg1.

Journal: Experimental neurology

Published: February 07, 2026

Transient receptor potential canonical 6 is critical for chronic lipopolysaccharide exposure-induced pulmonary injury and fibrosis.

Transient receptor potential canonical 6 is critical for chronic lipopolysaccharide exposure-induced pulmonary injury and fibrosis.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: January 16, 2026

HY-021068 improves neuronal ferroptosis by activating Nrf2 signaling in APP/PS1 Mice and Aβ1-42-induced HT22 cells.

HY-021068 improves neuronal ferroptosis by activating Nrf2 signaling in APP/PS1 Mice and Aβ1-42-induced HT22 cells.

Journal: European journal of pharmacology

Published: May 14, 2025

Chronic lipopolysaccharide exposure promotes cognitive impairments by activating TRPC6-AIM2 inflammasome signaling and the regulation of ginsenoside Rg1 in Trpc6-/- mice.

Chronic lipopolysaccharide exposure promotes cognitive impairments by activating TRPC6-AIM2 inflammasome signaling and the regulation of ginsenoside Rg1 in Trpc6-/- mice.

Journal: Behavioral and brain functions : BBF

Published: April 09, 2025

Ginsenoside Rg1 attenuates T2DM-induced renal damage and fibrosis by inhibiting TRPC6-ChREBP-TXNIP signaling.

Ginsenoside Rg1 attenuates T2DM-induced renal damage and fibrosis by inhibiting TRPC6-ChREBP-TXNIP signaling.

Journal: Journal of ethnopharmacology

Published: February 25, 2025

Knockout of Trpc6 attenuates T2DM-induced liver injury and inflammation by inhibiting CN-NFAT2-NLRP3 signalling in mice.

Knockout of Trpc6 attenuates T2DM-induced liver injury and inflammation by inhibiting CN-NFAT2-NLRP3 signalling in mice.

Journal: Pathology, research and practice

Published: April 23, 2024

Corrigendum to "Trpc6 knockout improves behavioral dysfunction and reduces Aβ production by inhibiting CN-NFAT1 signaling in T2DM mice" [Experimental Neurology 363 (2023) 114350/manuscript number: EXNR-22-846].

Corrigendum to "Trpc6 knockout improves behavioral dysfunction and reduces Aβ production by inhibiting CN-NFAT1 signaling in T2DM mice" [Experimental Neurology 363 (2023) 114350/manuscript number: EXNR-22-846].

Journal: Experimental neurology

Published: March 29, 2024

Ginsenoside Rg1 alleviates chronic inflammation-induced neuronal ferroptosis and cognitive impairments via regulation of AIM2 - Nrf2 signaling pathway.

Ginsenoside Rg1 alleviates chronic inflammation-induced neuronal ferroptosis and cognitive impairments via regulation of AIM2 - Nrf2 signaling pathway.

Journal: Journal of ethnopharmacology

Published: March 04, 2024

PLC-CN-NFAT1 signaling-mediated Aβ and IL-1β crosstalk synergistically promotes hippocampal neuronal damage.

PLC-CN-NFAT1 signaling-mediated Aβ and IL-1β crosstalk synergistically promotes hippocampal neuronal damage.

Journal: International immunopharmacology

Published: December 05, 2023

Corrigendum to "Ginsenoside Rg1 attenuates LPS-induced chronic renal injury by inhibiting NOX4-NLRP3 signaling in mice." [Biomed. Pharmacother. 150 (2022) 112936].

Corrigendum to "Ginsenoside Rg1 attenuates LPS-induced chronic renal injury by inhibiting NOX4-NLRP3 signaling in mice." [Biomed. Pharmacother. 150 (2022) 112936].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 01, 2023

Ginsenoside Rg1 attenuates lipopolysaccharide-induced chronic liver damage by activating Nrf2 signaling and inhibiting inflammasomes in hepatic cells.

Ginsenoside Rg1 attenuates lipopolysaccharide-induced chronic liver damage by activating Nrf2 signaling and inhibiting inflammasomes in hepatic cells.

Journal: Journal of ethnopharmacology

Published: October 04, 2023

Showing 1-12 of 63

Last Updated: 09/26/2026